ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced U.S. Urology Partners, one of the nation’s ...

ImmunityBio (IBRX) announced U.S. Urology Partners, one of the nation’s largest independent providers of urology and related specialty ...

Following the Bacillus Calmette-Guérin shortage, the first patient with bladder cancer has been dosed with recombinant ...

According to the latest study from BCC Research, "Technical Textiles: Global Markets," is expected to grow from $213.8 billion in 2024 to $284.0 billion by the end of 2029, at a compound annual growth ...

Tailored Brands, Inc. (the "Company"), a leading omnichannel specialty retailer of menswear, today announced the appointment of Julie B. Rosen and Lewis L. (Lee) Bird III as members of its Board of ...

This could lead to higher costs for ImmunityBio and impact the overall supply chain for rBCG/BCG. Furthermore, rBCG production is still complex and there is potential for bottlenecks, especially ...

for recombinant Bacillus Calmette-Guérin (rBCG) to address the current shortage of TICE® BCG in the U.S. As of March 2025, the U.S. stock market is experiencing increased volatility, with ...

Pre-market: 7:27:01 am GMT-5 ...